摘要
目的应用美洛昔康治疗骨关节炎,观察临床疗效。方法选取我院收治的160例骨关节炎患者为研究对象,时间为2017年1月至2019年1月,随机分为观察组和对照组,每组80例,对照组行双氯芬酸钠治疗,观察组行美洛昔康治疗,对比两组治疗有效率、不良反应发生率,另对比患者疼痛评分、生活质量治疗前后变化。结果观察组治疗有效率为97.50%(78/80)、不良反应发生率为6.25%(5/80),对照组治疗有效率为86.25%(69/80)、不良反应发生率为21.25%(17/80),两组对比,差异具有统计学意义(P<0.05,χ^(2)=7.015、8.077)。治疗前,两组患者疼痛评分和生活质量接近(P>0.05),治疗后,观察组患者疼痛评分为(1.50±0.40)分、生活质量为(56.30±4.80)分,对照组患者疼痛评分平均为(2.20±0.50)分、生活质量为(71.20±6.10)分,两组对比,差异具有统计学意义(P<0.05,t=4.016、18.772)。结论应用美洛昔康治疗骨关节炎疗效确切,安全性高,可有效控制患者疼痛问题,并提升患者生活质量。
Objective To treat osteoarthritis with meloxicam and observe the clinical effect.Methods One hundred and sixty patients with osteoarthritis admitted to our hospital from January 2017 to January 2019 were randomly divided into observation group and control group,80 cases in each group.The control group was treated with diclofenac sodium,the observation group was treated with meloxicam,comparing the effectiveness of the two groups of treatment,the incidence of adverse reactions,and comparing the pain scores of patients with changes in quality of life before and after treatment.Results The effective rate of the observation group was 97.50%(78/80),the incidence of adverse reactions was 6.25%(5/80),the effective rate of the control group was 86.25%(69/80),and the incidence of adverse reactions was 21.25%(17/80),the difference between the two groups was statistically significant(P<0.05,χ^(2)=7.015,8.077).Before treatment,the pain score and quality of life of the two groups were close(P>0.05).After treatment,the pain score of the observation group was(1.50±0.40),the quality of life was(56.30±4.80),and the pain score of the control group was(2.20±0.50)points,the quality of life was(71.20±6.10)points.The difference between the two groups was statistically significant(P<0.05,t=4.016,18.772).Conclusion The application of meloxicam in the treatment of osteoarthritis is effective and safe,which can effectively control the pain of patients and improve the quality of life of patients.
作者
杨春霞
YANG Chunxia(Dalian Zhuanghe Central Hospital,Dalian 116400,China)
出处
《中国医药指南》
2021年第30期91-92,共2页
Guide of China Medicine
